Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.
Assembly Biosciences, Inc. (ASMB) news on Stock Titan centers on the company’s progress in developing small-molecule therapeutics for serious viral diseases. Assembly Bio describes itself as a biotechnology company focused on herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections, and its news flow reflects clinical, scientific and corporate developments across these areas.
Investors following ASMB news can expect regular updates on clinical trial milestones. Recent press releases detail interim Phase 1b results for long-acting HSV helicase-primase inhibitor candidates ABI-5366 and ABI-1179 in participants with recurrent genital herpes, including reported reductions in HSV-2 shedding rates, high viral load shedding and genital lesion rates in certain dosing cohorts. News items also cover Phase 1b data for ABI-4334, a next-generation capsid assembly modulator candidate in chronic HBV infection, and Phase 1a interim data for ABI-6250, an oral HDV entry inhibitor candidate evaluated in healthy participants.
Another key theme in Assembly Bio’s news is its collaboration with Gilead Sciences. Company announcements describe Gilead’s rights to opt in to exclusive licenses for specific programs and report that Gilead has exercised its combined option to license the HSV helicase-primase inhibitor programs ABI-5366 and ABI-1179 for recurrent genital herpes. These items provide context on how the collaboration may influence development responsibilities, potential milestones and royalty structures.
Financial and corporate updates also feature prominently in ASMB news. Quarterly results outline collaboration revenue from Gilead, research and development spending on HSV, HBV and HDV programs, and general and administrative expenses. Additional releases describe equity financings, including an underwritten offering of common stock and warrants and a private placement with Gilead, along with the intended use of proceeds for general corporate purposes.
For investors and observers, the ASMB news feed offers a consolidated view of Assembly Biosciences’ clinical data disclosures, collaboration developments, financing activities and participation in scientific and investor conferences. Bookmarking this page can help track how the company’s antiviral pipeline and partnership with Gilead evolve over time.
Assembly Biosciences (Nasdaq: ASMB) has initiated a Phase 2 trial for its second-generation core inhibitor, ABI-H2158, targeting chronic hepatitis B infection. This randomized, placebo-controlled trial will involve 80 treatment-naïve patients, comparing 2158 with entecavir against a placebo. The trial aims to evaluate HBV DNA reduction and safety over 72 weeks. Previous Phase 1b results showed that 2158 was well tolerated and demonstrated significant antiviral activity. Clinical data from this trial will be presented at the upcoming EASL congress in August 2020.
Assembly Biosciences (ASMB) announced preclinical data from its immuno-oncology microbiome program showcased at the American Association for Cancer Research Virtual Annual Meeting II. The poster highlights the discovery of a live biotherapeutic product (LBP) targeting solid tumors, revealing single bacterial strains with significant anti-tumor activity. The program aims to enhance the efficacy of checkpoint inhibitors. Assembly’s lead candidate, ABI-M201, is in a Phase 1b trial for ulcerative colitis, while ABI-M301 is in preclinical stages for Crohn's disease.
Assembly Biosciences, Inc. (Nasdaq: ASMB) has regained worldwide rights to its microbiome gastrointestinal programs previously licensed to AbbVie, which has terminated their collaboration agreement. No safety or efficacy concerns were cited. The Company plans to explore strategic alternatives for ongoing development of its microbiome programs, including ABI-M201, currently in Phase 1b trials for ulcerative colitis. Assembly anticipates its cash reserves of $249.1 million will fund operations into 2022. The transition is expected to complete by Q4 2020.
Assembly Biosciences (Nasdaq: ASMB) announced inducement grants of stock options and restricted stock units to its Chief Scientific Officer, Dr. William Delaney, and eight new employees. Dr. Delaney received options to purchase 100,000 shares at an exercise price of $20.52 and 45,000 restricted stock units. The new employees received options for a total of 75,040 shares at $18.82 each. These awards are part of a recruitment strategy, complying with Nasdaq's inducement rules and are subject to vesting periods. The company specializes in therapeutics for hepatitis B and microbiome-related diseases.
Assembly Biosciences, Inc. (Nasdaq: ASMB) will hold its 2020 Annual Meeting of Stockholders virtually on June 11, 2020, at 8:00 AM PDT, due to the COVID-19 pandemic. Stockholders of record as of April 13, 2020, can participate via audio webcast, vote, and ask questions. Despite the transition to an online format, the previously distributed proxy materials remain valid for voting. Stockholders should log in at least 15 minutes early and can access support for any technical issues during the meeting.
Summary not available.